International Stem Cell CORP·4

Jun 23, 8:30 PM ET

MAIER PAUL V 4

Research Summary

AI-generated summary

Updated

International Stem Cell (ISCO) Director Paul V. Maier Receives 212,584-Share Award

What Happened

Paul V. Maier, a director of International Stem Cell Corp (ticker: ISCO), received two equity awards on 2026-06-11 covering a total of 212,584 shares (30,000 and 182,584). The grants are reported as derivative awards with an acquisition price of $0.00, meaning no cash was paid at grant. These are awards (not open-market purchases or sales) that vest over time rather than immediate stock purchases.

Key Details

  • Transaction date: 2026-06-11; Form 4 filed 2026-06-23 (appears to be a late filing—Form 4s are generally due within 2 business days).
  • Grants: 30,000 shares @ $0.00 and 182,584 shares @ $0.00 (total 212,584); reported as derivative awards.
  • Vesting (per filing footnotes):
    • 30,000 shares vest on the earlier of (a) June 11, 2027 or (b) the date of the next annual meeting after the grant.
    • 182,584 shares vest in equal quarterly increments through June 11, 2027, with the first increment vesting September 11, 2026.
  • Shares owned after the transaction: not specified in the provided filing summary.
  • Transaction code: A = Award/Grant (not a purchase/sale or option exercise).

Context

These awards are time-based equity grants (derivative instruments) that vest over the coming year; they do not represent an immediate sale or cash out. For retail investors, such grants are routine executive/board compensation and should be interpreted as compensation-related, not a direct market buy signal. The late filing may reduce transparency for a short period; it does not change the economic terms of the awards.